While approved therapies for advanced PCa already include specific genomic or proteomic tests for PARP inhibition and PSMA-directed radioligand therapy, a second wave of therapies based on omics stratification is rapidly approaching regulatory maturity. This evidence concerns the gene FOLH1 and posterior cortical atrophy.